Hailed as the largest Phase I deal in biotech history, Anadys Pharmaceuticals Inc. entered a potential $570 million agreement with Novartis Pharma AG to advance ANA975 and other Toll-like receptor 7 oral prodrugs for chronic hepatitis C and hepatitis B viruses. (BioWorld Today)